Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | TACR3 | P29371 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | FSHR | P23945 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471940 | 0.85 | TACR3 (0.44) | TSHRSMN1; SMN2OPRM1OPRL1TACR1 | |
| SCHEMBL2473487 | 0.81 | ALDH1A1 (0.50) | TSHRTACR1CYP3A4GAACYP2C19 | |
| SCHEMBL2470163 | 0.79 | TSHR (0.56) | TSHRSMN1; SMN2OPRM1TACR3OPRD1 | |
| SCHEMBL2701748 | 0.73 | CHRNA7 (0.49) | OPRM1OPRL1CHRNA7 | |
| SCHEMBL2471174 | 0.71 | NPC1 (0.52) | TSHRSMN1; SMN2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL11286492 | 0.69 | SIGMAR1 (0.50) | OPRM1OPRL1 | |
| SCHEMBL2467123 | 0.69 | ALDH1A1 (0.48) | OPRL1TACR1 | |
| SCHEMBL2701751 | 0.68 | SLC6A4 (0.65) | OPRM1OPRL1TACR1OPRK1CHRNA7 | |
| SCHEMBL2701337 | 0.67 | KMT2A (0.72) | TSHRSMN1; SMN2CYP2C19 | |
| SCHEMBL14252703 | 0.67 | OPRM1 (0.50) | TSHRSMN1; SMN2OPRM1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | TSHR 2555/4885SMN1; SMN2 4032/4885OPRM1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.